Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

for
Ovarian Cancer Recurrent
Location: Boston MA, New Haven CT, New York NY, Montreal,
Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT06843447

Phase 1, Phase 2, Recruiting

Lead-212 PSV359 Therapy for Patients With Solid Tumors

for
Pancreatic Ductal Adenocarcinoma, Gastric Cancer,
Location: New York NY, Miami FL, Pittsburgh PA, Cleveland OH,
Sponsor: Perspective Therapeutics

Sex: All

Age: 18 - 70+

Code: NCT06710756

Phase 1, Phase 2, Recruiting

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

for
Platinum-resistant Ovarian Cancer
Location: Newport Beach CA, El Segundo CA
Sponsor: ImmunityBio, Inc.

Sex: Female

Age: 18 - 70+

Code: NCT06710288

Phase 2, Recruiting

13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.

for
Ovarian Cancer, Ascites
Location: Victoria
Sponsor: British Columbia Cancer Agency

Sex: Female

Age: 18+

Code: NCT05025878

Recruiting

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

for
Ovarian Cancer
Location: Boston MA, New York NY, Paramus NJ, Bethlehem PA,
Sponsor: Daiichi Sankyo

Sex: Female

Age: 18+

Code: NCT06819007

Phase 3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

for
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Location: Philadelphia PA, Pittsburgh PA, Chicago IL, Madison WI,
Sponsor: University of Colorado, Denver

Sex: Female

Age: 18 - 70+

Code: NCT05887609

Phase 2, Recruiting

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

for
Germ Cell Tumor, Non-seminomatous Germ Cell Tumor,
Location: Indianapolis IN
Sponsor: Nabil Adra

Sex: All

Age: 18+

Code: NCT04804007

Phase 2, Recruiting

DOvEE - Diagnosing Ovarian & Endometrial Cancer Early

for
Ovarian Neoplasms
Location: Montreal
Sponsor: McGill University

Sex: Female

Age: 45+

Code: NCT02296307

Recruiting

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

for
Recurrent Ovarian Cancer
Location: Pittsburgh PA
Sponsor: Lan Coffman

Sex: Female

Age: 18+

Code: NCT05942300

Phase 1, Recruiting

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for
Ovarian Carcinoma
Location: Portland ME, Scarborough ME, Boston MA, Providence RI,
Sponsor: NRG Oncology

Sex: Female

Age: 35 - 50

Code: NCT04251052

Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for
Carcinoma, Non-Small Cell Lung,
Location: Boston MA, Newton MA, Shirley NY, Riverhead NY,
Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All

Age: 18+

Code: NCT04389632

Phase 1, Recruiting

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

for
Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma,
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute

Sex: All

Age: 18+

Code: NCT06855706

Recruiting

Patient Preferences for Precision Medicine: Determining Optimal Patient Quality of Life Using PARPi's

for
Ovarian Cancer, Quality of Life
Location: Saskatoon
Sponsor: University of Saskatchewan

Sex: Female

Age: 0+

Code: NCT06751303

Recruiting

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

for
Ovarian Cancer, Malignant Neoplasm of Uterus
Location: New York NY
Sponsor: Icahn School of Medicine at Mount Sinai

Sex: Female

Age: 18+

Code: NCT06040970

Phase 1, Phase 2, Recruiting

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

for
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms,
Location: Norfolk VA, Fairfax VA, Miami Beach FL,
Sponsor: Corcept Therapeutics

Sex: Female

Age: 18+

Code: NCT06906341

Phase 2, Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

for
Childhood Extracranial Germ Cell Tumor,
Location: St. John's, Halifax, Bangor ME, Portland ME,
Sponsor: Children's Oncology Group

Sex: All

Age: 0+

Code: NCT03067181

Phase 3, Recruiting

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

for
Head and Neck Squamous Cell Carcinoma (HNSCC),
Location: Columbus OH, Grand Rapids MI, Houston TX,
Sponsor: Tanabe Pharma America, Inc.

Sex: All

Age: 18+

Code: NCT06943521

Phase 1, Phase 2, Recruiting

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

for
Ovarian Cancer
Location: Maywood IL
Sponsor: Loyola University

Sex: All

Age: 18+

Code: NCT05983276

Phase 2, Recruiting

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

for
Ovarian Cancer
Location: Tampa FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: Female

Age: 18+

Code: NCT05316129

Phase 1, Recruiting

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

for
Ovarian Cancer, Cholangiocarcinoma Recurrent,
Location: Philadelphia PA, Tampa FL, Madison WI, Houston TX
Sponsor: Verismo Therapeutics

Sex: All

Age: 18+

Code: NCT05568680

Phase 1, Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial